Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Omvoh ® ▼ (mirikizumab)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk
How should Omvoh® (mirikizumab) devices be disposed of?
Omvoh (mirikizumab) pens or syringes must be disposed of in a sharps container.
Why should mirikizumab devices be disposed in a sharps container?
Mirikizumab devices i.e. pre-filled pens and syringes must be disposed of as a "sharp" because of the attached needles. The needles on the devices are permanently attached and cannot be taken off.
- Place the used devices in a closable puncture-resistant sharps container.
- DO NOT place used or unused devices in the household waste.
- Dispose of the sharps container as per community guidelines/local laws.1
How should unused mirikizumab be disposed of?
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.2
References
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Omvoh 100 mg solution for injection in pre-filled pen [summary of product characteristics] Eli Lilly Nederland B.V., The Netherlands (UK)
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 01 May 2023